Vancouver, British Columbia–(Newsfile Corp. – January 18, 2022) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“ Entheon” or the “Company“)announced that it has filed a preliminary short form base shelf prospectus dated January 14, 2022 (the “Preliminary Prospectus“) with the securities commissions in each of the provinces and territories of Canada.


Previous articlePT285 – Andrew Penn, NP – The Need for Nurses in Psychedelics, The Placebo Effect, and Appreciating the Subtle
Next articleRed Light Holland to Collaborate with Advocacy Group, Psychedelic Medicine Alliance Washington to Promote Proposed Psilocybin Legalization Bill in Washington State